Gsk (GLAXF) Equity Income (2009 - 2026)

Gsk's Equity Income history runs 10 years deep, the most recent figure standing at -$5.4 million for Q1 2026.

• In Q1 2026, Equity Income changed N/A year-over-year to -$5.4 million; the TTM figure through Mar 2026 stood at -$4.0 million (changed N/A YoY), while the FY2025 annual figure was $1.3 million, up 134.38% from the prior year.
• Equity Income was -$5.4 million for Q1 2026 at Gsk, down from -$1.3 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $5.4 million in Q3 2025 to a low of -$6.2 million in Q4 2023.
• Historically, Equity Income has averaged -$2.0 million across 5 years, with a median of -$2.3 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Equity Income tumbled 164.54% in 2023, then soared 515.41% in 2025.
• A 5-year view of Equity Income shows it stood at -$2.3 million in 2022, then sank by 164.54% to -$6.2 million in 2023, then jumped by 37.95% to -$3.9 million in 2024, then jumped by 65.45% to -$1.3 million in 2025, then slumped by 305.42% to -$5.4 million in 2026.
• The last three Equity Income figures came in at -$5.4 million (Q1 2026), -$1.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.